Women Health Expert GC-Rise Sponsors Nationwide Anti-Cancer Campaign

Jun 11, 2012, 09:00 ET from GC-Rise Pharmaceutical Co., Ltd

BEIJING, June 11, 2012 /PRNewswire-Asia/ -- GC-Rise Pharmaceutical Co. Ltd, in which European healthcare venture capital firm INVENTAGES holds a majority stake, has exclusively sponsored a nation-wide anti-tumor academic exchange event initiated by the Committee of Gynecological Oncology, Chinese Anti-Cancer Association.

The move shows GC-Rise's consistent commitment to do its part for the development of the women's health industry in China.

The program will consist of several symposiums in more than 10 cities throughout the country, focusing on the diagnosis, treatment as well as the improvement of post-treatment life quality concerning gynecological tumors.

The committee held its first symposium in Beijing on May 27, in which GC-Rise jointly explored how to improve life quality for women patients who have received tumor-removal operations with the medical experts.

"Post-operation treatment is just as important as the operation itself; the life quality of patients after the operations should be given high attention," said professor Sheng Xiugui, a senior committee member of the association.

Sheng cited Remifemin, introduced by GC-Rise, a herbal drug that treats some of the effects of menopause, as a preferred product to alleviate or eliminate the symptoms of menopause after operations or chemotherapy such as profuse sweating, insomnia or emotional instability.

GC-Rise introduced Remifemin from Germany at the end of 2008. After three years' expansion in China, its market share is now 11%, a top-three product in its segment.

This is not GC-Rise's first initiative aiming to contribute to the women's health industry within the academic world. The company also teams up with CMC to make its voice heard through the CMC-GC-Rise Journal

About GC-Rise Pharmaceutical Co. Ltd

GC-Rise Pharmaceutical Co. Ltd, established in 2008, is a wholly-owned foreign enterprise invested by INVENTAGES, a major European healthcare and biotechnology venture capital investor, focuses on women's health. Taking "Devoted to human healthcare and a better life" as our mission, the company makes full use of the business networks of our strategic partners in the United States, Europe and Japan, their rich experiences in clinical development, clinical trials and registration in China and their strong strength in distributions, hospital sales and marketing, so as to provide safe, novel and highly efficient medical products and treatment ideas for Chinese women patients.

Please log on to http://www.gc-rise.com/ to learn more.

SOURCE GC-Rise Pharmaceutical Co., Ltd